"Drag Pharma" describes the strategic, operational, and regulatory inertia that incumbents (Big Pharma) use to protect market share, or the unintended consequences of bureaucracy that stifle innovation. It is the art of not moving quickly.
No, this isn't a new autoimmune disease. It is the silent, systemic friction that slows down the drug development pipeline—often deliberately. drag pharma
Disclaimer: This post is for informational purposes only and does not constitute legal or investment advice. "Drag Pharma" describes the strategic
As investors and executives, we must stop asking "Is this drug safe?" and start asking "What is the drag coefficient?" Because a cure that arrives 5 years late is not a cure—it is a business decision. drag pharma